French translation and linguistic validation of the Raynaud's condition score.


Journal

Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 21 01 2019
accepted: 15 03 2019
pubmed: 27 4 2019
medline: 30 4 2020
entrez: 27 4 2019
Statut: ppublish

Résumé

The Raynaud's condition score is a 11-point scale severity score used in Raynaud's phenomenon clinical trials since 1998. The Raynaud's condition score diary has been recommended for use in clinical trials assessing efficacy of interventions on scleroderma related Raynaud's phenomenon. However, this score has never been formally validated in French. We thus performed a translation and a linguistic validation of the Raynaud's condition score through a forward/backward translations process followed by an expert review and cognitive patient interviews. The translations led to a French version of the Raynaud's condition score that was linguistically valid, and conceptually equivalent to the original English version. This "Score de Raynaud" will be usable to perform and harmonize clinical trials in French-speaking patients with secondary Raynaud's phenomenon.

Identifiants

pubmed: 31023622
pii: S0040-5957(19)30057-5
doi: 10.1016/j.therap.2019.03.002
pii:
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

627-631

Informations de copyright

Copyright © 2019 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Charles Khouri (C)

Pharmacovigilance unit, Grenoble Alpes university hospital, 38000 Grenoble, France; Inserm CIC1406, clinical pharmacology department, Grenoble Alpes university hospital, 38000 Grenoble, France; Inserm, UMR 1042-HP2, university Grenoble Alpes, 38000 Grenoble, France. Electronic address: CKhouri@chu-grenoble.fr.

Sophie Blaise (S)

Inserm, UMR 1042-HP2, university Grenoble Alpes, 38000 Grenoble, France; Department of vascular medicine, Grenoble university hospital, 38000 Grenoble, France.

Alicia Guigui (A)

Inserm CIC1406, clinical pharmacology department, Grenoble Alpes university hospital, 38000 Grenoble, France.

Claire Cracowski (C)

Inserm CIC1406, clinical pharmacology department, Grenoble Alpes university hospital, 38000 Grenoble, France.

Yannick Allanore (Y)

Service de rhumatologie A, hôpital Cochin, université Paris Descartes, 75014 Paris, France.

Eric Hachulla (E)

Service de médecine interne, Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), hôpital Claude Huriez, CHU de Lille, 59045 Lille, France.

Patricia Senet (P)

Service de dermatologie et allergologie, hôpital Tenon, groupe hospitalier universitaire Paris Est, Assistance publique-Hôpitaux de Paris, 75020 Paris, France.

Mathieu Roustit (M)

Inserm CIC1406, clinical pharmacology department, Grenoble Alpes university hospital, 38000 Grenoble, France; Inserm, UMR 1042-HP2, university Grenoble Alpes, 38000 Grenoble, France.

Jean-Luc Cracowski (JL)

Inserm CIC1406, clinical pharmacology department, Grenoble Alpes university hospital, 38000 Grenoble, France; Inserm, UMR 1042-HP2, university Grenoble Alpes, 38000 Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH